Replies to post #31917 on RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

By giving Samyang such a big stake in the company, the incentive to string cor along with a bogus partnership negotiation, with the ultimate goal of scooping up the IP is no longer in place. If a deal isn't done, cor will shareprice will drift downward, and Samyang walks off with the IP.

Also cor management's interests are in alignment with shareholders again: the higher the shareprice at the time of conversion, the smaller the stake Samyang will ultimately have.

[neuroinv]

In a vacuum, we've seen price suppression work. But IF Cortex is able to finish that partnership, that will supersede any such machinations.

Secondly--we have become so innured to the concept that everyone circling around Cortex is a speculator/manipulator that the possibility that someone has actually made an 'investment' seems vaguely naive or foreign. I don't know Samyang, but I am pretty familiar with one of their other positions, NeuralStem. A fetal-source stem cell company (NIH's Karl Johe) which has finally gotten permission to start implanting stem cells in ALS patients. Seems an unlikely choice for someone trying to find targets for manipulation.

It will be interesting to watch the share price over the next month or so--and particularly after any actual news from Cortex.

NeuroInvestment